The invention of the "pill" for women was undoubtedly one of the most significant medical, social and cultural events of the 20 th century [1] . While nature has sweetened procreation with the pleasures of sex to guarantee human reproduction, the pill was the culmination of a millennial-long development of methods to disentangle procreation from sex and has had a substantial impact on society, e.g., on family planning, morality and demography, not to mention economic and political impact. An equivalent pharmacological male method is not yet available.
Female contraception is very effective. Nevertheless, 50% of the 1,000,000 conceptions occurring every day worldwide remain unplanned, of which 150,000 are terminated by abortion, an intervention that will end fatally for 500 of these women. Although improved distribution and utilization of female contraceptive methods might ameliorate this situation, the contribution of a male contraceptive is well worth considering. Men enjoy the pleasures of sex, but can do little to contribute to the tasks of family planning -a pharmacological male contraceptive is surely long overdue.
Moreover, the risks of contraception would also be more fairly shared between women and men. Representative surveys have shown that a pharmacological male contraceptive would be acceptable to large segments of the population in industrial nations, and would thus contribute to further stabilization of population dynamics. It might also help developing countries whose exponential population growth endangers economic, social and medical progress. Last but not least, male contraception can be considered an outstanding issue in the political field of gender equality
Choices For the Male
For the male, there are ways to eliminate both procreation and sex at the same time. Such methods have been used in the past and are still being practiced on a limited scale. Castration has been employed since ancient time to destroy enemies by abolishing their ability to reproduce and transmit their genes. Until the end of the imperial period in China (1912), men were willing to sacrifice their testicles (and often with them their lives) in return for high-ranking positions and political influence at the emperor's court. Meanwhile, in the West, up until almost the same time, some promising boys were forced to give up their manhood for the sake of preserving their prepubertal voice and achieving fame as singers, often without success [2] . Abstinence is a less bloody means of eliminating procreation, but few men are willing to give up both sex and procreation for extended periods of time, let alone their entire lives.
Traditional male methods of contraception such as periodic abstinence or coitus interruptus are associated with a relatively high rate of unwanted pregnancy and also cause a disturbance in sexual activity. Condoms are the oldest barrier method available. However, when using condoms, conception rates are relatively high, with 12 out of 100 couples conceiving during the first year of use (Pearl index = 12). Condom use has increased since the beginning of the AIDS epidemic, but more for protection from HIV infection and other sexually transmitted diseases than for contraceptive purposes [3] . Vasectomy is a safe and relatively simple surgical method for male contraception. The rate of unwanted pregnancies after vasectomy is less than 1%. The drawback to vasectomy is that it is not easily reversible. Achieving fatherhood after vasectomy requires either surgical reversal or sperm extraction from a testicular biopsy and intracytoplasmatic sperm injection into the ovum. Only about 50% of these men will become fathers in the end.
Given the disadvantages of these mechanical male methods, what then are the prerequisites for an ideal male contraceptive? It should -be applied independently of the sexual act, -be acceptable for both partners, -not interfere with libido, potency, or sexual activity, -have neither short-or long-term toxic side effects, -have no impact on eventual offspring, -be rapidly effective and fully reversible, -be as effective as comparable female methods.
For the past 40 years, hormonal approaches to male contraception have been tested clinically. In the following, these developments will be reviewed taking the above prerequisites into account.
     2. Principle of Hormonal Male Contraception
Of all the different experimental approaches and pharmacological methods tested so far for male contraception, hormonal methods come closest to fulfilling the criteria set out above. The endocrine feedback mechanism operating between hypothalamus, pituitary and testes is the summary, it should be noted that in all these many clinical trials, only very few untoward side effects were reported, including mild acne and moderate weight gain as a more frequent symptom, the latter due to the anabolic effect of testosterone. A recently performed placebocontrolled clinical trial for male contraception demonstrated that several symptoms previously ascribed to the steroid regimen used, also occur in the placebo group [55] . Minimal serious adverse events were registered in this multitude of trials. In all studies, sperm counts returned to normal levels as a review of major studies also revealed [61] [63] , but not until the 1970s did investigations start to exploit this phenomenon for male contraception. As in most hormonal male contraceptive studies to date, in the early studies, sperm concentrations and counts were used as surrogate parameters for efficacy.
The first efficacy study of testosteronebased hormonal male contraception was sponsored by the World Health Organization (WHO) [5] and included 10 centers on four continents. Healthy fertile participants were given 200 mg of the longer-acting testosterone enanthate weekly by im injection. One hundred fifty-seven men (70%) reached azoospermia after 6 months of treatment and entered the efficacy phase for a further year, during which no other contraceptive was used by the couple. Only one pregnancy was reported in this first proof-of-principle study. Although the basis on which hormonal approaches to male contraception rest. Its goal is to suppress spermatogenesis and to reduce sperm concentration, if possible, to azoospermia or at least to a sperm concentration low enough to provide contraceptive protection (≤ 1×10 6 sperm per mL ejaculate).
Sperm production and secretion of testicular testosterone are so closely interwoven that it has remained impossible to interrupt spermatogenesis by hormonal means without inhibiting androgen production. Inhibition of follicle-stimulating hormone (FSH) alone, e.g., by antibodies, leads to reduction of sperm concentration but not to azoospermia, as monkey studies have shown. Suppression of both FSH and luteinizing hormone (LH) would indeed lead to azoospermia, but would also induce symptoms of androgen deficiency which affects libido, potency, male role behavior and general metabolic processes (erythropoesis, protein, mineral and bone metabolism). For this reason inhibition of gonadotropins will always necessitate androgen administration.
Thus, the principle of hormonal male contraception is based on (1) suppression of LH and FSH, (2) depletion of intratesticular testosterone and atrophy of spermatogenesis, and (3) substitution of peripheral testosterone to maintain androgenicity.
At first sight, testosterone itself would be the steroid of choice as it simultaneously suppresses the gonadotropins and maintains androgenicity. However, studies showed that by administration of testosterone alone, azoospermia could only be achieved in two-thirds of Caucasian men, so that another gonadotropin-suppressing agent must be added to interrupt spermatogenesis as completely as possible. Gonadotropin-releasing hormone (GnRH) analogues and several different steroid combinations and delivery systems such as oral, transdermal, subcutaneous and intramuscular (im) have been examined. Each has its respective merits and drawbacks ( Fig. 1B and C). efficacy of this study was very high, it cannot be used to determine the overall efficacy of testosterone alone as a contraceptive because only men who became azoospermic could enter the efficacy phase while the others were excluded.
In order to clarify the question whether men developing oligozoospermia can be considered infertile, a second worldwide multicenter efficacy study involving 357 couples followed [11] . In this study, azoospermia again proved to be a most effective prerequisite for contraception. If sperm concentration, however, failed to drop below 3 × 10 6 /mL ejaculate, resulting pregnancy rates were higher than when using condoms. When sperm concentrations decreased below 3 × 10 6 /mL, which was the case in 98% of the participants, then protection was not as effective as for azoospermic men, but was better than that offered by condoms (Fig. 2 ).
Even if these WHO studies represented a breakthrough by confirming the principle of action, they did not offer a practicable method. For a method requiring weekly im injections is not acceptable for broad use. Moreover, several months, often up to one year, are required before sperm production reaches significant suppression. For this reason, current research is concentrating on the development of long-acting testosterone preparations and on methods to hasten the onset of effectiveness.
Testosterone Buciclate
As long-acting testosterone preparations appeared more promising in terms of practicability and acceptability, WHO and the NIH initiated a synthesis program for such preparations [64] through which the long-acting testosterone ester testosterone buciclate was identified. This molecule showed a half-life of 29.5 days when tested in hypogonadal men, much longer than the 4.5 days of testosterone enanthate [65] . Suppression of spermatogenesis was comparable to that of weekly testosterone enanthate injections, reaching azoospermia in three out of eight volunteers after a single injection of 1200 mg of testosterone buciclate [6] . Despite its promising pharmacokinetic profile, no industrial partner could be found to undertake development of this preparation.
Testosterone Undecanoate
Initially, testosterone undecanoate was studied as an oral preparation in volunteers of Caucasian origin [56] . Subjects were given a daily dose of 240 mg over a period of 12 weeks, but only one out of seven volunteers reduced sperm output sufficiently for contraception. This low effectiveness is probably due to the short half-life of testosterone undecanoate when given orally. Even if administered four times a day, the peaks are not sufficient to suppress gonadotropins consistently and thereby to achieve azoospermia.
While testosterone undecanoate had been developed as an oral preparation in Europe, it was turned into an injection in China, using tea seed oil as a vehicle and is used as such in China for hypogonadism and in trials for male contraception. Back in Europe, the half-life of this Chinese preparation could be extended even further when dissolved in castor oil and is now available for clinical use in 1000 mg depot injections [66] .
In the clinical trials in China, testosterone undecanoate alone administered every 4 weeks resulted in azoospermia in all Chinese men who received a dose of 1000 mg and in azoospermia or severe oligozoospermia in 95% of Chinese men who received a dose of 500 mg during a 4-6-month suppression phase [12] . In the ensuing phase III study involving 305 couples, an efficacy phase followed the suppression phase, and no pregnancies were initiated by men exhibiting azoospermia or severe oligozoospermia [16] . However, reappearance of sperm occurred in six men during the efficacy phase; one pregnancy was attributed to "sperm rebound". Side effects observed in subjects were all typical of elevated testosterone serum levels. The largest efficacy study to date was also performed in China, based on a loading dose of 1000 mg followed by monthly injections of 500 mg testosterone undecanoate. Eight-hundred ninety-eight men entered the efficacy phase during which only 9 pregnancies were recorded. This represents a pregnancy rate of 1.1 per 100 person-years [17] . Thus, in China, testosterone undecanoate provides better protection against pregnancy than condom use. Although injection intervals of four weeks appeared to be an achievement over the weekly injections of testosterone enanthate, the participants in a Chinese study considered the frequency of injections the most inconvenient part of this regimen [67] . Would testosterone undecanoate in castor oil also be used in China, this complaint could certainly be overcome.
In a first contraceptive trial of testosterone undecanoate in castor oil, 1000 mg was injected into 14 Caucasian volunteers at 6-week intervals. Eight of 14 men achieved azoospermia [13] . Although this rate of azoospermia is not different from that achieved with testosterone enanthate alone, the longer injection interval represents a significant advantage. A later pharmacokinetic study concluded that 8-week intervals of 1000-mg injections would be sufficient for contraceptive purposes [43] . Considering that 10-to 14-week intervals of 1000 mg testosterone undecanoate are required for substitution of hypogonadal men, about one third more testosterone is required for contraception in normal volunteers.
Testosterone Pellets
Pellets consisting of pure testosterone are used for substitution in hypogonadism in some countries. In male contraceptive studies, the sperm suppressing effect was comparable to weekly testosterone enanthate injections [68] . The disadvantage of minor surgery required for insertion under the abdominal skin is compensated for by their low price. Spontaneous extrusion may be a disadvantage.
19-Nortestosterone
When searching for preparations with longer lasting effectiveness, 19-nortestosterone-hexoxyphenylpropionate was tested. Its spectrum of effects is very similar to that of testosterone and it has been used as an anabolic steroid since the 1960s. The 19-nortestosterone ester injected every 3 weeks enabled azoospermia to be reached by as many men as by testosterone enanthate. Thus, the 19-nortestosterone ester is as effective as testosterone enanthate but allows a longer interval between injections [69] .
Although effective in suppressing spermatogenesis and without any notable side effects in the studies, it could not be determined whether this synthetic androgen would have any unwanted effects with long-term use. The lack of negative reports from widespread use of 19-nortestosterone in athletes cannot be taken as evidence for its clinical application as systematic evaluations in athletes have not been published.
7α-Methyl-19-Nortestosterone
The synthetic androgen 7α-methyl-19-nortestosterone (MENT) offers an approximately 10-fold higher potency to suppress pituitary gonadotropins than does testosterone. In contrast to testosterone, there is no 5α-reduction so that effects on the prostate could be minimal. A first dose-finding study showed that MENT administered in subcutaneous implants was as effective as testosterone given alone [15] . The potential of these implants either alone or in combination with gestagen implants is currently being investigated by the Population Council.
Androgens Combined With GnRH Analogues

GnRH Agonists
The pituitary-inhibiting effects of GnRH agonists are well known from their use in females and in the therapy of prostate cancer. After an initial phase of gonadotropin stimulation, they suppress gonadotropins and, consequentially, intratesticular testosterone by GnRH receptor down-regulation. However, trials for hormonal male contraception in which mostly testosterone was added showed that sperm numbers were only insufficiently reduced, thus rendering these agonists unsuitable as male contraceptives [70] .
GnRH Antagonists
GnRH antagonists lack the effect of initial gonadotropin release as they competitively inhibit pituitary GnRH receptors, thus leading to a more immediate onset of azoospermia. This could be demonstrated by small clinical studies using various GnRH antagonists in addition to a testosterone preparation [71] . Out of 47 volunteers participating in various clinical trials with different GnRH-antagonists, azoospermia was achieved in 39 subjects and oligozoospermia ≤ 1×10 6 sperm per mL ejaculate occurred in one additional volunteer, while only three men maintained sperm concentrations above 3×10 6 /mL ejaculate. Of the more recently developed GnRH antagonists, acycline has been tested in male contraceptive trials. Although acycline given alone had a potent gonadotropin-suppressing effect [72] , the addition of acycline to a combination of testosterone gel plus depot medroxyprogesterone acetate (DMPA) did not increase the suppression of sperm achieved by the steroids alone [30] .
Despite these encouraging results, the requirement for daily or weekly injections and the high costs of the available preparations have hindered the further development of GnRH antagonists for hormonal male contraception. Promising attempts to use the GnRH antagonists only to initiate azoospermia and then maintain this by androgens alone were not pursued further [73, 74] .
Androgens Plus Gestagens
The potency of gestagens to suppress gonadotropins is well known from female contraceptives where gestagens effectively supplement estrogens. Numerous studies combining androgens (mainly testosterone) with various gestagens have been performed over the past 4 decades in order to identify a regimen suited for male contraception (Fig. 3) .
Unfortunately, a systematic comparison of the different gestagens with regard to their contraceptive potency in males has never been performed. Even worse, a Cochrane Review analyzing 45 clinical trials came to the conclusion that the studies comprised too small numbers of volunteers so that significant differences between the various steroid combinations could not be detected [75] . Moreover, not all studies observe strict criteria for randomized controlled trials. However, it should be kept in mind that many of these trials were performed as proof of principle and not necessarily as trials for registration with the regulatory authorities. In addition, single centers are financially and logistically unable to cope with the numbers of volunteers and criteria demanded by regulatory agencies. Stimulated by researchers and by public demand, the pharmaceutical industry finally performed a trial fulfilling the Cochrane criteria -and left the field! [55] In the following, important studies are briefly summarized to highlight the cumbersome and often frustrating development ( Table 1 ).
The gestagens used in these studies derive either from 19-nortestosterone or from 17-hydroxyprogesterone and are all being used in female contraceptives (Fig. 3). 3.3.1. Depot Medoxyprogesterone Acetate From early studies in the 1970s initiated by the WHO and the Population Council, DMPA emerged as a gestagen with great potential in male contraception [76] . The combination of DMPA with 19-nortestosterone in 3-week intervals first tested in Caucasians [25] was especially promising in Indonesian men [24] .
One of the very few efficacy studies aiming at pregnancy rates also used DMPA, however, in combination with testosterone pellets [28] . In this Australian study, 53 of 55 volunteers suppressed to azoospermia and during the 1-year efficacy phase, no pregnancy occurred. However, the discontinuation rate in this study was high and onset of and recovery from azoospermia took several months.
In order to test whether one of the two steroid entities could be self-administered, the addition of a testosterone transdermal gel to the DMPA injections (300 mg/3 months) was tested [30] . The results were comparable to those from trials where DMPA was combined with injectable testosterone.
Levonorgestrel
Oral levonorgestrel, when combined with testosterone enanthate im slightly enhanced the effect of testosterone enanthate alone [10] . Similarly, when combined with testosterone undecanoate im the additional effect of oral levonorgestrel remained marginal in Caucasian men [13] but seemed to increase effectiveness in Chinese men [39] .
In a comparative study, when levonorgestrel implants were combined with testosterone pellets, an additive effect of levonorgestrel was seen in Caucasian men, but not in Chinese men who responded equally well to testosterone pellets alone [38] .
When MENT implants were combined with levonorgestrel implants in different doses, a clear dose-dependent effect could be observed, but it remains undetermined whether implants with sufficiently long duration can be manufactured; non-biodegradable implants that have to be removed surgically from the implantation site when contraceptive protection is no longer required appear impractical for widespread use unless they can be left in situ for long periods [77] .
Norethisterone
The injectable depot preparation norethisterone enanthate (NETE) and the orally effective norethisterone acetate (NETA) are hydrolyzed to release the active compound norethisterone, which can be 5α-reduced to 5α-norethisterone and aromatized to ethinyl estradiol. While norethisterone has strong androgenic activity (~ 10% of testosterone), 5α-noresthisterone also shows antiandrogenic properties.
Of 14 men who received 200 mg NETE combined with 1000 mg testosterone undecanoate every 6 weeks, 13 achieved azoospermia [40] . Further investigations showed that the injection intervals could be extended to 8 weeks [42] or that testosterone undecanoate could be combined with oral NETA without loss of effectiveness [41] . Based on these findings, together with CONRAD, WHO is planning a phase II efficacy study involving 400 couples in 8 centers worldwide [78].
Cyproterone Acetate
The orally effective antiandrogen cyproterone acetate (CPA) has strong gestagenic properties. In early studies combining oral CPA with testosterone enanthate injections, the sperm-suppressing effects were considerable, but the antiandrogenic effects (e.g., reflected by decreased hematocrit) were undesirable. However, when combining 1000 mg testosterone undecanoate every 6 weeks with 20 mg CPA daily initially, followed by only 2 mg CPA/day, the initial suppression of spermatogenesis could be maintained and antiandrogenic effects prevented [46] . 
Desogestrel and Etonogestrel
Desogestrel is an orally effective gestagen which becomes active after conversion to etonogestrel. Etonogestrel can be administered directly as an implant (Implanon). In combination with testosterone enanthate or testosterone pellets, desogestrel showed good suppression of spermatogenesis [47, 49] . Etonogestrel implants combined with testosterone pellets s.c. resulted in a high azoospermia rate, although it took up to 28 weeks to reach this goal in some individuals [53] .
In the first (and so far last) industrysponsored trial, Organon and Schering decided to test etonogestrel implants with testosterone undecanoate injections in various combinations [55] . This study involved 354 volunteers in seven treatment groups receiving either placebo or 750-1000 mg testosterone undecanoate every 10-12 weeks with two doses of etonogestrel for 42-44 weeks. Ninety percent of treated men suppressed spermatogenesis to ≤ 1×10 6 /mL ejaculate.
Although the combination of an implant with injections may not appear too attractive for practical use, the study had a high success rate and could have formed the basis for a phase III efficacy study. Unfortunately, both companies discontinued their male contraception programs when they were taken over by other firms who were at that stage not interested in male contraception.
     4. Acceptability of Male Contraception
One of the reasons why the pharmaceutical industry has not continued to further develop a male contraceptive at this stage may be doubts about the possible acceptability of such a pharmacological method. However, recently, public interest in male methods for contraception has notably grown. It is increasingly expected that men share with their partners not only the advantages but also the risks of family planning. As risks tend to increase with duration of use, sharing contraception between men and women would reduce dangers for each partner. Similarly, the use of condoms for contraception varies from country to country with a worldwide average of 5.7%. It is to be expected that the percentage of men willing to practice contraception varies between cultures and with methods available. According to asurvey in Hongkong and Shanghai 10 years ago, half the men interviewed were willing to take a daily contraceptive pill; in Edinburgh and Capetown two thirds were willing to do so [79, 80] . After almost 50 years of female oral contraception, the attitude of men towards new methods of male contraception has changed. Worldwide, surveys showed men willing to use pharmacological contraceptive methods [81] (Fig. 4) .
     5. Responsibility For the Development of Contraceptives
The world population has tripled in the last 50 years and is approaching 7 billion. Less developed countries bear the onus of this enormous population growth while the population in industrialized nations is largely stable -due to use of contraceptive methods. The population explosion creates minimal surmountable ecologic and economic problems. Medical progress has decisively lowered mortality, particularly of children, so that life expectancy worldwide is currently 64.2 years for men and 68.6 years for women. Ever more people reach reproductive age. If medical progress allows increasing number of people to achieve reproductive age, causing overpopulation, then medicine must also provide contraceptive methods in order to maintain or restore a balance between reproduction and death. It has become clear that the Millennium Development Goals cannot be achieved with the current level of population growth [82] . It goes without saying that a newly developed male contraceptive would not suddenly resolve population problems, but a male method could contribute to the resolution, especially as research into female methods for contraception is similarly on the decline [83] . In addition, women increasingly demand that men share the responsibility and risks of family planning and men, on the other hand, want to regain some of the reproductive power they surrendered to women since the advent of modern female contraceptives [84, 85] . This should be reason enough for the pharmaceutical industry to actively develop male contraceptives. While a large proportion of clinical research is driven by the pharmaceutical Figure 4 . Multinational male fertility control survey among 9342 men who were asked the question: "If available, would you be willing to use the new male fertility control method?" (adapted from [81] ).
industry, in the case of male contraception, industry fails. Without the longrange perspective and endurance of institutions and organizations such as NICHD, CONRAD, Population Council, WHO, some medical research councils and few foundations, male contraception would long have been abandoned. The principle and effectiveness of hormonal male contraception has been demonstrated in many studies. The fact that the majority of clinical trials on hormonal male contraception have been published in high-ranking journals is important. This emphasizes the high priority the scientific community attributes to these endeavors. Investigators are so convinced of the validity of the concept of hormonal male contraception that they drafted recommendations for regulatory approval for male hormonal contraception at their annual summit meetings (since 1997) [86] . Little more is required to convince industry to bring this development to fruition.
Comparing the situation with the development of the female pill, the lack of public advocacy for male contraception is striking. Male contraception lacks prominent advocates as the development of female contraception benefited from personalities such as Margaret Sanger (1879-1966) and Katherine McCormick (1875-1967). Hormonal male contraception requires similar advocacy to finally result in a marketable product.
